Literature DB >> 12815475

Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF.

C Kaplinsky1, L Trakhtenbrot, I Hardan, M Reichart, M Daniely, A Toren, N Amariglio, G Rechavi, S Izraeli.   

Abstract

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is frequently used to mobilize CD34+ cells in healthy donors and patient with malignant diseases prior to peripheral blood stem cell (PBSC) harvest. To analyze the effects of rhG-CSF on morphology and genotype of white blood cells, a novel multiparametric cell scanning system that combines morphologic, immune and genotypic analyses of the same cells was used. We report here that tetraploid myeloid cells are present in the peripheral blood of donors treated with rhG-CSF. The tetraploidy was detected in up to 0.6% of differentiated myeloid cells and all observed CD34+ cells were diploid. Thus, short treatment with rhG-CSF of PBSC donors induces numerfical chromosomal alterations in a small subset of mature myeloid cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815475     DOI: 10.1038/sj.bmt.1703902

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

1.  Effects of granulocyte-colony-stimulating factor on Monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors.

Authors:  Matthew J Olnes; Andrea Poon; Susan J Miranda; Loretta Pfannes; Zachary Tucker; Kelsey Loeliger; Hesed Padilla-Nash; Yu Ying Yau; Thomas Ried; Susan F Leitman; Neal S Young; Elaine M Sloand
Journal:  Transfusion       Date:  2011-08-29       Impact factor: 3.157

Review 2.  A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies.

Authors:  B E Shaw; D L Confer; W Hwang; M A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

3.  Expression of granulocyte colony stimulating factor receptor in human colorectal cancer.

Authors:  X Yang; F Liu; Z Xu; C Chen; X Wu; G Li; J Li
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

4.  Congenital X-linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6.

Authors:  Raffaele Renella; Katelyn Gagne; Ellen Beauchamp; Jonathan Fogel; Aleksej Perlov; Mireia Sola; Thorsten Schlaeger; Inga Hofmann; Akiko Shimamura; Benjamin L Ebert; Klaus Schmitz-Abe; Kyriacos Markianos; Kristi Murphy; Liang Sun; Shira Rockowitz; Piotr Sliz; Dean R Campagna; Timothy A Springer; Christopher Bahl; Suneet Agarwal; Mark D Fleming; David A Williams
Journal:  Am J Hematol       Date:  2021-11-03       Impact factor: 10.047

Review 5.  Effects and safety of granulocyte colony-stimulating factor in healthy volunteers.

Authors:  Paolo Anderlini
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

6.  Second cancers in patients with the Ewing sarcoma family of tumours.

Authors:  Fariba Navid; Catherine Billups; Tiebin Liu; Matthew J Krasin; Carlos Rodriguez-Galindo
Journal:  Eur J Cancer       Date:  2008-03-18       Impact factor: 9.162

7.  Long-term inhaled granulocyte macrophage-colony-stimulating factor in autoimmune pulmonary alveolar proteinosis: effectiveness, safety, and lowest effective dose.

Authors:  Spyros A Papiris; Panagiotis Tsirigotis; Likurgos Kolilekas; Georgia Papadaki; Andriana I Papaioannou; Christina Triantafillidou; Anastasia Papaporfyriou; Anna Karakatsani; Konstantinos Kagouridis; Matthias Griese; Effrosyni D Manali
Journal:  Clin Drug Investig       Date:  2014-08       Impact factor: 2.859

8.  Canadian supportive care recommendations for the management of neutropenia in patients with cancer.

Authors:  C T Kouroukis; S Chia; S Verma; D Robson; C Desbiens; C Cripps; J Mikhael
Journal:  Curr Oncol       Date:  2008-01       Impact factor: 3.677

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.